Bifogade filer
Kurs
+5,04%
Likviditet
0,64 MSEK
Kalender
Tid* | ||
2026-01-28 | 08:00 | Bokslutskommuniké 2025 |
2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-07-17 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-05-06 | N/A | Årsstämma |
2025-04-23 | 08:00 | Kvartalsrapport 2025-Q1 |
2025-01-28 | 08:00 | Bokslutskommuniké 2024 |
2024-10-22 | - | Kvartalsrapport 2024-Q3 |
2024-07-16 | - | Kvartalsrapport 2024-Q2 |
2024-05-08 | - | X-dag ordinarie utdelning PROB 1.30 SEK |
2024-05-07 | - | Årsstämma |
2024-04-23 | - | Kvartalsrapport 2024-Q1 |
2024-01-26 | - | Bokslutskommuniké 2023 |
2023-10-24 | - | Kvartalsrapport 2023-Q3 |
2023-07-18 | - | Kvartalsrapport 2023-Q2 |
2023-05-05 | - | X-dag ordinarie utdelning PROB 1.30 SEK |
2023-05-04 | - | Årsstämma |
2023-04-26 | - | Kvartalsrapport 2023-Q1 |
2023-01-27 | - | Bokslutskommuniké 2022 |
2022-10-21 | - | Kvartalsrapport 2022-Q3 |
2022-07-15 | - | Kvartalsrapport 2022-Q2 |
2022-05-06 | - | X-dag ordinarie utdelning PROB 1.30 SEK |
2022-05-05 | - | Årsstämma |
2022-04-26 | - | Kvartalsrapport 2022-Q1 |
2022-02-02 | - | Bokslutskommuniké 2021 |
2021-10-22 | - | Kvartalsrapport 2021-Q3 |
2021-07-26 | - | Kvartalsrapport 2021-Q2 |
2021-05-10 | - | X-dag ordinarie utdelning PROB 1.10 SEK |
2021-05-07 | - | Årsstämma |
2021-04-23 | - | Kvartalsrapport 2021-Q1 |
2021-02-09 | - | Bokslutskommuniké 2020 |
2020-10-21 | - | Kvartalsrapport 2020-Q3 |
2020-07-17 | - | Kvartalsrapport 2020-Q2 |
2020-05-14 | - | X-dag ordinarie utdelning PROB 1.00 SEK |
2020-05-13 | - | Årsstämma |
2020-04-24 | - | Kvartalsrapport 2020-Q1 |
2020-02-11 | - | Bokslutskommuniké 2019 |
2019-10-25 | - | Kvartalsrapport 2019-Q3 |
2019-07-19 | - | Kvartalsrapport 2019-Q2 |
2019-05-08 | - | X-dag ordinarie utdelning PROB 0.00 SEK |
2019-05-07 | - | Årsstämma |
2019-04-29 | - | Kvartalsrapport 2019-Q1 |
2019-02-13 | - | Bokslutskommuniké 2018 |
2018-11-06 | - | Kvartalsrapport 2018-Q3 |
2018-08-13 | - | Kvartalsrapport 2018-Q2 |
2018-05-03 | - | X-dag ordinarie utdelning PROB 0.00 SEK |
2018-05-02 | - | Årsstämma |
2018-05-02 | - | Kvartalsrapport 2018-Q1 |
2018-01-25 | - | Bokslutskommuniké 2017 |
2017-10-25 | - | Kvartalsrapport 2017-Q3 |
2017-07-19 | - | Kvartalsrapport 2017-Q2 |
2017-05-05 | - | X-dag ordinarie utdelning PROB 1.00 SEK |
2017-05-04 | - | Kvartalsrapport 2017-Q1 |
2017-01-24 | - | Bokslutskommuniké 2016 |
2016-10-18 | - | Kvartalsrapport 2016-Q3 |
2016-07-15 | - | Kvartalsrapport 2016-Q2 |
2016-06-29 | - | Extra Bolagsstämma 2016 |
2016-04-28 | - | X-dag ordinarie utdelning PROB 1.00 SEK |
2016-04-27 | - | Årsstämma |
2016-04-27 | - | Kvartalsrapport 2016-Q1 |
2016-01-26 | - | Bokslutskommuniké 2015 |
2015-10-22 | - | Kvartalsrapport 2015-Q3 |
2015-07-16 | - | Kvartalsrapport 2015-Q2 |
2015-04-24 | - | X-dag ordinarie utdelning PROB 0.85 SEK |
2015-04-23 | - | Årsstämma |
2015-04-23 | - | Kvartalsrapport 2015-Q1 |
2015-01-28 | - | Bokslutskommuniké 2014 |
2014-10-29 | - | Kvartalsrapport 2014-Q3 |
2014-10-29 | - | Analytiker möte 2014 |
2014-08-19 | - | Kvartalsrapport 2014-Q2 |
2014-04-30 | - | X-dag ordinarie utdelning PROB 0.75 SEK |
2014-04-29 | - | Årsstämma |
2014-04-29 | - | Kvartalsrapport 2014-Q1 |
2014-01-23 | - | Bokslutskommuniké 2013 |
2013-10-22 | - | Kvartalsrapport 2013-Q3 |
2013-08-20 | - | Kvartalsrapport 2013-Q2 |
2013-04-25 | - | X-dag ordinarie utdelning PROB 0.75 SEK |
2013-04-24 | - | Årsstämma |
2013-04-24 | - | Kvartalsrapport 2013-Q1 |
2013-01-24 | - | Bokslutskommuniké 2012 |
2012-10-18 | - | Kvartalsrapport 2012-Q3 |
2012-09-28 | - | Kapitalmarknadsdag 2012 |
2012-08-16 | - | Kvartalsrapport 2012-Q2 |
2012-04-26 | - | Årsstämma |
2012-04-26 | - | Kvartalsrapport 2012-Q1 |
2012-01-25 | - | Bokslutskommuniké 2011 |
2011-10-19 | - | Kvartalsrapport 2011-Q3 |
2011-07-19 | - | Kvartalsrapport 2011-Q2 |
2011-04-29 | - | X-dag ordinarie utdelning PROB 0.50 SEK |
2011-04-29 | - | X-dag bonusutdelning PROB 0.5 |
2011-04-28 | - | Årsstämma |
2011-04-28 | - | Kvartalsrapport 2011-Q1 |
2011-01-26 | - | Bokslutskommuniké 2010 |
2010-10-20 | - | Kvartalsrapport 2010-Q3 |
2010-07-20 | - | Kvartalsrapport 2010-Q2 |
2010-04-23 | - | X-dag ordinarie utdelning PROB 0.50 SEK |
2010-04-22 | - | Årsstämma |
2010-04-22 | - | Kvartalsrapport 2010-Q1 |
2010-01-27 | - | Bokslutskommuniké 2009 |
2009-10-21 | - | Kvartalsrapport 2009-Q3 |
2009-08-18 | - | Kvartalsrapport 2009-Q2 |
2009-05-07 | - | X-dag ordinarie utdelning PROB 0.00 SEK |
2009-05-06 | - | Årsstämma |
2009-04-22 | - | Kvartalsrapport 2009-Q1 |
Beskrivning
Land | Sverige |
---|---|
Lista | Mid Cap Stockholm |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
Today, on World Mental Health Day, Probi launches Probi Sense, a brand-new probiotic food supplement reducing stress and improving mental well-being. The new product will shortly become available directly to consumers through pharmacies and selected retailers across Sweden, Denmark and Norway.
Probi Sense contains Probi's unique and well-documented lactic acid bacteria strain Lactiplantibacillus plantarum HEAL9 (HEAL9[®]), as well as the minerals zinc, iodine and magnesium. The product, underpinned by four clinical studies demonstrating its positive effects, is designed to support mental well-being by maintaining normal memory, concentration and reducing fatigue[1].
"With Probi Sense, we can offer our Nordic consumers a product that not only promotes physical health, but also mental health. We are proud to launch a product supported by multiple clinical studies that meets the growing need for mental well-being in today's society," says Alexia Wilhelmsson, Marketing Manager at Probi.
The gut is often referred to as the 'second brain' due to the two-way communication between the gastrointestinal tract and the brain. Through this close interaction, the gut flora can influence our mental and emotional health.
Mental health supplements are one of the fastest growing areas on the global dietary supplement market. Between 2017-2021, there was a 30% growth in launches of probiotics targeting mental health, indicating that the field, also referred to as "psychobiotics", is a rapidly growing niche in the market[2]. According to the World Health Organization (WHO), mental health is of critical importance to all people worldwide. Mental health needs are great, but efforts are currently insufficient[3]. With this as a background, Probi sees an opportunity to contribute to improving global wellbeing with Probi Sense.
Three initial studies on HEAL9 showed significant improvements in cognitive function, in terms of learning and working memory, mood, sleep and inflammation linked to stress. A fourth study, published earlier this year, showed that HEAL9 reduces inflammation and improves cognitive function in older individuals. An additional fifth study, which was recently published, showed that HEAL9 reduced cognitive impairment and inflammation in both the gut and brain using a mouse model of Alzheimer's disease. This further confirms HEAL9's benefits in Gut-Brain health while also offering hope for future preventative measures in the early stages of Alzheimer's.
For more information about the product, please visit www.probi.se.
For more information, please contact:
Lisa Jalakas, Global Content Strategy Manager, Probi AB,
E-mail: lisa.jalakas@probi.com,Tel: +46 721 93 63 22
Martina Pettersson, Global Marketing Director, Probi AB,
E-mail: martina.pettersson@probi.com (anita.johansen@probi.com),Tel: +46 766 33 11 66
[1]Zinc and iodine contribute to normal cognitive function. Magnesium helps to reduce fatigue and exhaustion.
[2]Lumina Intelligence (March 2022) "The gut-brain axis: Psychobiotic opportunity in 25 countries".
[3]World mental health report: Transforming mental health for all (who.int) (https://www.who.int/publications/i/item/9789240049338)
ABOUT PROBI
Probi® is a global company focused exclusively on researching, manufacturing, and delivering probiotics for supplements and functional food. We are experts at managing stable, live bacteria from R&D through every stage of the manufacturing process and are dedicated to making the health-enhancing benefits of probiotics available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical documentation. Since our founding in 1991 at Sweden's Lund University, Probi has expanded its operations to more than 40 markets. We hold more than 400 patents globally. Probi had sales of 628 MSEK in 2023. Probi's shares are listed on Nasdaq Stockholm, Mid-cap, and there were around 3,400 shareholders on December 31, 2023.